Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trilucent breast implants

This article was originally published in The Gray Sheet

Executive Summary

Product liability suit filed Aug. 10 in California federal court related to development, manufacture or sale of the "potentially dangerous" soy-based breast implants names Inamed, AEI (formerly Collagen Aesthetics), Cohesion Technologies, TUV, LipoMatrix, and Washington University, St. Louis as defendants. Filed by Miami attorney Jeffrey Herman of the law firm Herman & Mermelstein, the suit follows a June advisory issued by Britain's Medical Devices Agency after reports of rupture and toxicity were linked to the implants (1"The Gray Sheet" June 12, p. 12). Roughly 9,000 procedures were performed in Europe between 1995-1999; about 2,000 woman have had their implants removed
Advertisement

Related Content

Trilucent Breast Implants Should Be Explanted - UK Medical Devices Agency
Trilucent Breast Implants Should Be Explanted - UK Medical Devices Agency
Advertisement
UsernamePublicRestriction

Register

MT013739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel